Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Cancer drug may inhibit growth of cysts in patients with inherited form of kidney disease

A cancer drug called bosutinib may inhibit the growth of cysts in patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

24 Aug 2017

Mayo Clinic study reveals link between senescent cells and bone loss in mice

Mayo Clinic researchers have reported a causal link between senescent cells - the cells associated with aging and age-related disease - and bone loss in mice.

21 Aug 2017

Scientists discover novel therapeutic strategy to treat aggressive subgroup of lung cancer

Research conducted by a team of Norton Thoracic Institute scientists on a novel therapeutic avenue for an aggressive and difficult to treat subgroup of lung cancer was published in the August 15, 2017 issue of Cancer Research.

17 Aug 2017

FDA approves first extended adjuvant therapy to lower risk of breast cancer recurrence

The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.

18 Jul 2017

Inhibition of cell receptors clears toxic proteins, cuts inflammation and improves cognition in animal models

Researchers have found cell receptors abnormally overexpressed in post-mortem brains of those with Parkinson's and Alzheimer's diseases, and that they can be inhibited in animal models to clear toxic protein buildup, reduce brain inflammation, and improve cognitive performance.

17 Jul 2017

Researchers show effective oral treatment option for patients with rheumatoid arthritis

Patients suffering from rheumatoid arthritis are treated for around six months with the standard anti-rheumatic agent methotrexate, to which many patients respond very well.

19 Jun 2017

Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer

Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).

5 Jun 2017

Combining oral drug with personalized cell therapy can lead to complete remission in CLL patients

Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center

31 May 2017

FDA approves new drug and chemotherapy combination for treatment of adult patients with AML

The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy.

28 Apr 2017

Stivarga receives expanded FDA approval for treatment of liver cancer

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.

28 Apr 2017

Scientists discover promising target to treat highly aggressive brain tumor in infants

Using state-of-the-art gene editing technology, scientists from Ann & Robert H. Lurie Children's Hospital of Chicago have discovered a promising target to treat atypical teratoid/rhabdoid tumor (AT/RT) – a highly aggressive and therapy resistant brain tumor that mostly occurs in infants.

11 Apr 2017

Study identifies potential Achilles heel of kinase-driven cancers

Scientists identify two signaling proteins in cancer cells that make them resistant to chemotherapy, and show that blocking the proteins along with chemotherapy eliminate human leukemia in mouse models.

22 Mar 2017

Penn studies provide new understanding of lung cancer progression and prevention

Treating the brain with a preventative course of radiation may help Small Cell Lung Cancer (SCLC) patients - whose tumors often spread to their brain -- live longer, according to a new study from researchers in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.

16 Mar 2017

Drug could activate innate anti-tumor immunity to eradicate aggressive prostate cancer in mice

Cabozantinib, a drug already used to treat patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils - the first-responders of the immune system - to infiltrate the tumor, where they triggered an immune response that led to tumor clearance.

9 Mar 2017

Study provides insight into how microRNA may amplify effects of drug treatment in liver cancer

Treatment options for liver cancer are often limited and almost exclusively involve transplantation if possible, or local chemoembolization and radiofrequency ablation.

17 Feb 2017

Researchers uncover mechanism of resistance used by triple negative breast cancer

Breast cancer cells are evasive, finding ways to bypass drugs designed to stop their unchecked growth.

20 Jan 2017

Researchers discover Hedgehog signaling pathway is key to formation of gastrointestinal stromal tumors

Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.

1 Nov 2016

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North Carolina Lineberger Comprehensive Cancer Center-led study.

4 Oct 2016

New drug holds potential for treating advanced mastocytosis

Most people have never heard of mastocytosis. It's a rare, sometimes deadly, immune disorder. Now new research may help those with advanced mastocytosis and possibly many more people, too.

6 Sep 2016

Researchers discover novel neuroprotection strategies to slow progression of Parkinson's disease

Using a robust model for Parkinson's disease, University of Alabama at Birmingham researchers and colleagues have discovered an interaction in neurons that contributes to Parkinson's disease, and they have shown that drugs now under development may block the process.

20 Jul 2016